Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
reaction mass of mono to tetra(lithium and/or sodium)3-amino-10-[4-(4-amino-3-sulfonatoanilino)-6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to tetra(lithium and/or sodium)3-amino-10-[4,6-bis(4-amino-3-sulfonatoanilino)-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to penta(lithium and/or sodium)10,10´-diamino-6,6',13,13´-tetrachloro-3,3'-[6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10-amino-6,6',13,13'-tetrachloro-10´[4-(4-amino-3-sulfonatoanilino)-[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10,10'-diamino-6,6',3,3'[(2-sulfonato)-1,4-phenylenediiminobis[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate
EC number: 430-200-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Registered substance
- IUPAC Name:
- Registered substance
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- distd.
- Details on oral exposure:
- daily dose;
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- UV/VIS spectrometry
- Duration of treatment / exposure:
- Test duration: 28 days; at the end of the treatment period five animals/sex were maintained untreated for two weeks;
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
Male: 5 animals at 50 mg/kg bw/day
Male: 5 animals at 200 mg/kg bw/day
Male: 10 animals at 1000 mg/kg bw/day
Female: 10 animals at 0 mg/kg bw/day
Female: 5 animals at 50 mg/kg bw/day
Female: 5 animals at 200 mg/kg bw/day
Female: 10 animals at 1000 mg/kg bw/day - Control animals:
- yes, concurrent vehicle
- Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- clinic examinations: twice daily
body weight: weekly and on the day preceding termination;
food consuption: per group per week;
food efficieny: no
water consumption: no;
Ophthaloscopic examination: yes
Haematology: yes
clinical chemistry: yes
Urinalysis: yes
Neurobehavioural Examination: yes - Sacrifice and pathology:
- All animals necropsied as scheduled were weighed on the day of necropsy and descriptions of all macroscopic abnormalities were recorded. Necropsies were
performed by experienced prosectors supervised by an experienced veterinary pathologist. At the end of the treatment or recovery period the animals were
anesthetized by intraperitoneal injection of sodium pentobarbitone and killed by exsanguination.
Samples from all animals at necropsy and fixed in neutral phosphate buffered 4 % formaldehyde solution;
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- males treated at 1000 mg/kg/d
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- MORTALITY
No unscheduled deaths occurred during the course of the study in animals of either sex treated with Bthe substance at a daily dose level of 50 mg/kg, or in
females treated at 200 mg/kg.
One male treated daily at 1000 mg/kg died on day 23 of the treatment period. A further male and one female in this group, both of which were designated as
recovery group animals, died on day 29 and day 28 (respectively).
One male animal treated at 200 mg/kg died on day 5 of the treatment period. A post mortem examination revealed bluish colored fluid in the thoracic cavity. This
finding is suggestive of mechanical damage due to the dosing procedure, although no evidence of traumatic injury was noted at necropsy. Therefore, the evidence
for test article-induced death is equivocal.
All other animals survived the scheduled treatment period, and the treatment-free period where applicable.
CLINICAL SIGNS
Daily clinical examinations revealed treatment-related effects at all dose levels employed. Blue colored feces occurred in all animals treated with the substance at
all dose levels. All other clinical signs were restricted to the group treated with the substance at a daily dose level of 1000 mg/kg. Sedated behavior and ruffled fur
occurred in animals surviving the treatment period, but multiple clinical signs occurred in animals that died prematurely.
BODY WEIGHT AND WEIGHT GAIN
There were no treatment-related effects on the body weight development of animals of either sex treated with the substance at 50 or 200 mg/kg, or in females
treated at 1000 mg/kg.
The overall body weight gain of males treated at 1000 mg/kg was lower than the controls. There was no effect on body weight gain during the recovery period.
FOOD CONSUMPTION
There were no treatment-related effects on the absolute and relative food consumption of animals of either sex treated with the substance at 50 or 200 mg/kg, or
in females treated at 1000 mg/kg.
The overall mean food consumption of the male group treated at 1000 mg/kg was 8% lower than the controls. There was no effect on food consumption during the
recovery period.
OPHTHALMOSCOPIC EXAMINATION
No ocular abnormalities attributable to the administration of the test article occurred in either sex at any dose level, up to and including the highest daily dose level,
1000 mg/kg.
HAEMATOLOGY
There were no treatment-related changes in the hematological profile of either sex treated at a daily dose level of 50 or 200 mg/kg.
Red blood cell count was slightly reduced and circulating reticulocyte numbers and neutrophil / lymphocyte ratio were increased in males treated at 1000 mg/kg.
Hemoglobin and methemoglobin concentrations of the female group treated at 1000 mg/kg were elevated after 4 weeks of treatment.
No treatment-related effects were apparent at the end of the treatment-free period in either males or females.
CLINICAL CHEMISTRY
There were no treatment-related changes in the clinical biochemistry parameters of either males or females treated daily at 50 or 200 mg/kg.
Plasma ALAT activities were significantly higher in both sexes after 4 weeks of treatment. The male group also showed a significantly higher uric acid concentration
and calcium ion concentration than the control group. The female group also showed significantly higher plasma triglyceride concentration, higher GGT activity and
significantly lower total protein, albumin and globulin concentrations than the controls. The albumin / globulin ratio was unaffected.
No other treatment-related clinical biochemistry effects were apparent after 4 weeks of treatment and none were apparent at the end of the treatment-free period in
either males or females.
URINALYSIS
There were no treatment-related changes in urinalysis parameters in either males or females treated daily at 50 mg/kg or in males treated at 200 mg/kg.
Animals of both sexes treated at 1000 mg/kg showed significantly higher urine volumes than the control groups and significantly lower specific gravity and
osmolality. Urine pH was also significantly higher than the controls in female animals.
In the female group treated at 200 mg/kg, urine osmolality was significantly lower and pH was significantly higher than the control values.
All other measured physiological parameters and all urine cellular or chemical constituents of the treated groups were similar to, and not significantly different from
the control values.
No treatment-related effects were apparent at the end of the treatment-free period in either males or females.
NEUROBEHAVIOUR
Quantitative assessment of locomotor activity revealed consistently lower activity in both male and female animals treated at 1000 mg/kg.
Quantitative measurement of forelimb and hindlimb grip strength revealed no statistically significant differences from the control groups at any of the dose levels
employed.
ORGAN WEIGHTS
There were no treatment-related changes in the organ weights or ratios of male and female groups treated daily at 50 or 200 mg/kg, or in males treated at 1000 mg/
kg.
The adrenal weight and both ratios of the female group treated at 1000 mg/kg were significantly higher than the control group values after 4 weeks of treatment.
There were no other treatment-related effects on organ weights after 4 weeks of treatment.
At the end of the treatment-free period, female adrenal weights and all other organ weights and ratios in males and females, with the exception of ovary weight,
were not significantly different from the control values. Group mean ovary weight and ratios were significantly lower than control group values at this time. In the
absence of an effect on this parameter after 4 weeks of treatment and in the absence of any histological findings in the ovary, the lower ovary weight is considered
to be of no toxicological consequence.
GROSS PATHOLOGY
At the end of the treatment-free period, a bluish discoloration remained in some tissues and organs of animals treated at 1000 mg/kg. The kidneys and lymph
nodes of all animals remained bluish in color. Occasional animals also showed a persistence of a bluish color in the lungs, stomach and small and large intestine.
HISTOPATHOLOGY: NON-NEOPLASTIC
At 1000 mg/kg the treatment-related lesions persisted during the recovery period in the kidneys, urinary bladder, liver and lung. Treatment-related lesions also occurred in the spleen of male animals previously treated at 1000 mg/kg.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on the findings of reduced urine osmolality, elevated urine pH and renal pelvic dilation in some animals treated at 200 mg/kg/day.
- Dose descriptor:
- LOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on the findings of reduced urine osmolality, elevated urine pH and renal pelvic dilation in some animals treated at 200 mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Classified as: Not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.